Diabetes
Is tirzepatide linked to fewer deaths than GLP-1 drugs?
Open access · cc by · source: Europe PMC
In 140,308 US adults with type 2 diabetes, tirzepatide was associated with lower all-cause mortality (AHR 0.58) and fewer major cardiovascular and kidney events than GLP-1 receptor agonists.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
In US EHR data, starting tirzepatide associated with fewer deaths and CV/kidney events than starting a GLP-1 RA.
Among 140,308 matched US adults with type 2 diabetes, tirzepatide vs a GLP-1 receptor agonist associated with lower all-cause mortality (AHR 0.58), MACEs (AHR 0.80), kidney events (AHR 0.52), AKI (AHR 0.78), and MAKEs (AHR 0.54) over a median 10.5 months, with larger HbA1c and weight drops.
Evidence for the claim as stated.
FAERS biliary signals were clearer for DPP-4 inhibitors than for GLP-1 RAs as a class, with agent exceptions.
Among 2,215 biliary FAERS reports, DPP-4 inhibitors had ROR 3.09 (sitagliptin 3.46). Overall GLP-1 RAs were called non-significant (ROR 1.60), but semaglutide (4.06) and liraglutide (3.88) signaled; serious outcomes were 76.88% of DPP-4 vs 51.55% of GLP-1 reports.
Scope note — matched T2D EHR mortality/CV outcomes ≠ spontaneous biliary reporting ratios
Limits the claim's scope: a different population, assay, or outcome.
A T2D EHR comparison of tirzepatide versus GLP-1 RAs is not a pancreatitis incidence study, not a biliary FAERS ROR, and is not a T1D add-on trial. Class talk still needs the indication, comparator, and design named.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
A T2D EHR comparison of tirzepatide versus GLP-1 RAs is not a pancreatitis incidence study, not a biliary FAERS ROR, and is not a T1D add-on trial. Class talk still needs the indication, comparator, and design named.
History
When this study was placed
Dated entries from the concept change log — when this paper was added or removed as support, challenge, or qualifier on a claim.
Placed as a scope qualifier on GLP-1 receptor agonists
Among 2,215 biliary FAERS reports, DPP-4 inhibitors had ROR 3.09 (sitagliptin 3.46). Overall GLP-1 RAs were called non-significant (ROR 1.60), but semaglutide (4.06) and liraglutide (3.88) signaled; serious outcomes were 76.88% of DPP-4 vs 51.55% of GLP-1 reports.
Placed as supporting evidence on GLP-1 receptor agonists
Among 140,308 matched US adults with type 2 diabetes, tirzepatide vs a GLP-1 receptor agonist associated with lower all-cause mortality (AHR 0.58), MACEs (AHR 0.80), kidney events (AHR 0.52), AKI (AHR 0.78), and MAKEs (AHR 0.54) over a median 10.5 months, with larger HbA1c and weight drops.
Placed as supporting evidence on GLP-1 receptor agonists
A T2D EHR comparison of tirzepatide versus GLP-1 RAs is not a pancreatitis incidence study and is not a T1D add-on trial. Class talk still needs the indication, comparator, and design named.
Study at a glance
- Design
- Cohort — Retrospective TriNetX cohort of US adults with type 2 diabetes initiating tirzepatide vs GLP-1 RA (June 2022–June 2023), with 1:1 propensity-score matching
- N
- N=140308 · 140,308 patients: 14,834 tirzepatide and 125,474 GLP-1 RA before matching; median follow-up 10.5 months
- Population
- US adults ≥18 years with type 2 diabetes starting tirzepatide or a GLP-1 RA, without baseline stage 5 CKD/kidney failure or recent MI/stroke
- Outcome
- All-cause mortality (primary); MACEs, kidney events, AKI, and major adverse kidney events
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
Is tirzepatide linked to fewer deaths than GLP-1 drugs?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
Cohort included 140,308 patients with type 2 diabetes.
Findings In this cohort study of 140 308 patients with type 2 diabetes, treatment with tirzepatide was associated with significantly lower hazards of all-cause mortality and major adverse cardiovascular and kidney events compared with GLP-1 RA.
Tirzepatide vs GLP-1 RA all-cause mortality AHR was 0.58 (95% CI 0.45–0.75).
We observed a lower hazard of all-cause mortality in patients given tirzepatide compared with GLP-1 RA (AHR, 0.58; 95% CI, 0.45-0.75; P < .001) ( Table 2 ; Figure 2 ; Figure 3 ).
Key findings
After median 10.5 months, 0.6% vs 1.1% died on tirzepatide vs GLP-1 RA (AHR 0.58). MACEs (AHR 0.80), kidney events (AHR 0.52), AKI (AHR 0.78), and MAKEs (AHR 0.54) were also lower, with greater HbA1c and weight drops.
Methodology
Used TriNetX records of adults initiating tirzepatide or a GLP-1 RA, excluded advanced kidney failure and recent stroke/MI, matched on 48 variables, and compared mortality, MACEs, and kidney outcomes with Cox models.
Limitations
Observational matching cannot prove tirzepatide causes fewer deaths; residual confounding, short follow-up, and US EHR coverage limit causal and global claims.
Related papers in this topic
Same topic cluster — not a recommendation engine.